The classical approach was to understand how genes transcribe to mRNA, and how mRNA translates to polypeptides; how those are cleaved by the cell, and fold in 3D space; and how those 3D shapes results in actual biological function. It required real-world measurement, experiment, and modeling in silico using biophysical models. Those are all hard research efforts. And it seems like the mindset now is: we've done enough hard research, let's feed what we know into a model, hope we've chosen the right hyperparameters, and see what we get. Hidden in the weights and biases of the model will be that deeper map of the real world that we have not yet fully grasped through research.
But the AI cannot provide a 'why'. Its network of weights and biases are as unintelligible to us as the underlying scientific principles of the real world we gave up trying to understand along the way. When AI produces a result that is surprising, we still have to validate it in the real world, and work backwards through the hard research to understand why we are surprised.
If AI is just a tool for a shotgun approach to discovery, that may be fine. However, I fear it is sucking a lot of air out of the room from the classical approaches. When 'AI' produces incorrect, misleading, or underwhelming results? Well, throw more GPUs at it; more tokens; more joules; more parameters. We have blind faith it'll work itself out.
But because the AI can never provide a guarantee of correctness, it is only useful to those with the infrastructure to carry out those real-world validations on its output, so it's not really going to create a paradigm shift. It can provide only a marginal improvement at the top of the funnel for existing discovery pipelines. And because AI is very expensive and getting more so, there's a pretty hard cap on how valuable it would be to a drugmaker.
I know I'm not the only one worried about a bubble here.